Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
Ocular Therapeutix (OCUL) Stock Price & Analysis
1,367 Followers
OCUL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.00 - $11.31
Previous Close$7.85
Volume1.17M
Average Volume (3M)2.57M
Market Cap
$1.22B
Enterprise Value$1.10B
Total Cash (Recent Filing)$195.81M
Total Debt (Recent Filing)$83.39M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 05, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding154,888,915
10 Day Avg. Volume3,202,442
30 Day Avg. Volume2,565,277
Standard Deviation0.28
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)10.62
Price to Sales (P/S)16.56
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.88
Enterprise Value/Gross Profit20.76
Enterprise Value/Ebitda-16.29
Forecast
1Y Price Target
$16.00Price Target Upside103.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Ocular Therapeutix News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAxpaxli has a high probability of success in SOL given its unique design leveraging the drug’s durability advantage over Eylea.
Management And ExecutionManagement is executing well with axpaxli poised to be the first long-acting TKI with pivotal data in wet AMD and a clinical program designed for differentiated claims.
Regulatory ProgressThe FDA agrees to amend the SPA for the Phase 3 SOL trial of axpaxli, which should accelerate enrollment in the wet AMD trial.
Bears Say
Clinical TrialsDuravyu missed the primary endpoint in the Phase 2 PAVIA trial with 5% and 0% of patients receiving 3 and 2 mg doses achieving a two-step DRSS response rate at nine months vs. 5% in the sham control arm.
Financial PerformanceNet loss was $64.8M, or ($0.49) per share, higher than estimated due to certain one-time expenses.
Stock PerformanceOCUL shares are down ~12% after response rates in HELIOS came in below the approved anti-VEGFs.
---
Ownership Overview
14.36% Insiders
8.01% Mutual Funds
13.64% Other Institutional Investors
63.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $2.00 and its highest was $11.31 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Currently, no data Available
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on May 07, 2024. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.298.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -$0.22.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 154,888,920 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -3.035%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Among the largest hedge funds holding Ocular Therapeutix’s share is Perceptive Advisors LLC. It holds Ocular Therapeutix’s shares valued at 30M.
---
Ocular Therapeutix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (103.82% Upside)
$16.00 (103.82% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 87%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $138.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.73%
12-Months-Change
Fundamentals
Return on Equity
-55.19%
Trailing 12-Months
Asset Growth
319.18%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
---
OCUL Earnings Call
Q3 2023
0:00 / 0:00
---
OCUL Stock 12 Month Forecast
Average Price Target
$16.00
▲(103.82% Upside)
Technical Analysis
Best Analysts Covering OCUL
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+46.71%
reiterated a buy rating last month
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +46.71% per trade.
---